Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01569828 | Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function | PHASE2 | COMPLETED | 12 | — | — | Mar 1, 2009 | Sep 1, 2009 | Sep 29, 2015 | 3 | Germany, Russia +1 |
Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696
Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696
Summary statistics for plasma PK parameters following 5 days QD dose of 400mg LCZ696
| Arm | Type | Description |
|---|---|---|
| Renal Impaired Subjects | EXPERIMENTAL | once daily administration of 400 mg LCZ696 for 5 days |
| Healthy Volunteers | EXPERIMENTAL | once daily administration of 400 mg LCZ696 for 5 days |
| Name | Type | Description |
|---|---|---|
| LCZ696A | DRUG | - |
Inclusion Criteria: \- Exclusion Criteria: \-